Chinese AI companies are in crisis mode, and they've found what they think is a cure: OpenClaw. But according to analysis from OvernightAI, it's more like a morphine drip than actual medicine. The analogy is stark—OpenClaw temporarily numbs the pain of billions in sunk investments and zero revenue, but it doesn't cure the underlying disease.

The Money Pit Problem

The diagnosis is straightforward: Chinese AI companies have spent tens of billions on infrastructure, over a billion on marketing, and hundreds of millions monthly serving models—all for what? Zero. Nada. Nothing. Despite amassing over 100 million weekly active users across their chatbot apps, not a single Chinese AI company has launched a paid tier. Why? Because Chinese consumers don't pay for software, and no company dares to test that assumption fearing user base annihilation. The enterprise side is doing slightly better, but still orders of magnitude behind Anthropic and OpenAI—who are seeing exponential revenue takeoff while Chinese players stagnate.

The OpenClaw Marketing Circus

Enter OpenClaw. When it went viral, Chinese AI companies saw API usage spike and convinced themselves they'd found their lifeline. The logic: more OpenClaw users = more tokens sold = revenue. So they mobilized everything. Tech and business media got flooded within days. Billboards went up. Subway screens ran ads. Then—bizarrely—even state-owned media joined the chorus. That's weird because these outlets have one job: amplify party propaganda about Taiwanese separatists, Japanese politicians, and China's blooming tech sector. Writing about a GitHub project (banned in China) founded by someone who just joined OpenAI, requiring technical skills 99% of people don't have? That's a South Park episode. But the sidewalk tents really stole the show. Tencent set up literal booths where people could walk in with their computers and get OpenClaw installed for them. The genius idea of scaling AGI by lining people up on sidewalks—chef's kiss. This is what happens when rationality exits the building and panic sets in.

Why It's an Opioid—Not a Cure

Here's the thing: OpenClaw isn't a mass market product. Most people don't want to set up dev environments, manage API keys, write access control rules, or deal with the instability of a bleeding-edge open source project. The early adopters are hackers and tech enthusiasts—people already comfortable with the command line. That's a niche. The marketing campaigns will pull in new users, API traffic will spike like someone on a morphine drip, and then reality hits. Users will try it for a few days, realize it's not what they imagined, and bounce. The revenue growth evaporates. Companies end up with nothing after burning massive resources on campaigns that converted zero normies into long-term users. They've lost focus on actual model and product development, all while the disease progresses.

Key Takeaways

  • Chinese AI companies have spent tens of billions with zero consumer revenue to show for it
  • OpenClaw is a developer tool, not a mass market product—most people can't use it
  • Marketing campaigns (media blitz, billboards, sidewalk tents) won't convert non-technical users
  • State-owned media covering a banned GitHub project is peak absurdity
  • Temporary usage spikes won't solve the underlying revenue problem

The Bottom Line

This is classic junkie behavior. Chinese AI companies are chasing a high instead of solving their disease—and when the opioid wears off, they'll be even further behind. The ones who figure out actual revenue models will survive. Everyone else is just buying time. This piece originally appeared on OvernightAI via Hacker News.